eieich, March 31, 2025: Biotest AG (ISIN DE0005227201, ISIN DE0005227235) has today concluded a delisting agreement with its major shareholder, Grifols, S.A., which holds approximately 97.14 % of the ...

If you’re eyeing Biotest and wondering whether now is the right moment to buy, hold, or move on, you’re in good company. The stock has been resting at €28.4, and though its short-term moves have been ...

Biotest, a subsidiary of Grifols, announced that the US FDA granted approval for its plasma protein therapy Yimmugo earlier today (17 June). Yimmugo is an intravenous immunoglobulin therapy developed ...

Dreieich, 19 September 2025. Biotest AG announces that, after careful consideration, the Management Board has deemed admissible the request received in writing from Grifols S.A. on 1 August 2025 ...

This document is not, and should not be regarded asinvestment advice or a recommendation, regarding any particular investment. As at the date of publication, the author has a long or short position in ...

ROCKAWAY, N.J., Aug. 18 Biotest Diagnostics Corporation(Biotest) -- the U.S. subsidiary of German-based Biotest AG, a worldwidesupplier of traditional and automated blood bank solutions -- announces ...

Biotest AG: Grifols acquires majority of voting rights in Biotest 25.04.2022 / 13:18 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Grifols acquires majority of ...

Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation) 14.11.2022 / 09:30 CET/CEST The issuer is solely responsible for the content of this ...

Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year. This represents an increase of 83.6 % compared to revenue of € 117.2 ...

ADMA will acquire BPC’s plasma-based fractionation and purification plant in Boca Raton, FL and plans to resolve issues at the facility noted in an FDA warning letter. ADMA Biologics, a late-stage ...

Biotest Pharmaceuticals has sold its U.S. therapy business, which includes its Boca Raton headquarters and plasma production center, to ADMA Biologics of Ramsey, N.J. The $40 million deal gives ...

FRANKFURT (Reuters) - Employees at German blood plasma products specialist Biotest, including its finance chief, are under investigation by German prosecutors over allegations of bribery in Russia.